In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

“Some patients also receive chemotherapy, but the data are mixed on its effectiveness and it’s also very toxic, so we were ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Findings, demonstrated by the phase 2 PERLA trial, were presented at the 2024 Society for Immunotherapy of Cancer (SITC) ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Agenus Inc. ( (AGEN) ) has released its Q3 earnings. Here is a breakdown of the information Agenus Inc. presented to its investors. Agenus Inc.

This study investigated patients with primary lung cancer who received PET/CT scan, a medical imaging test, and subsequently ...